Literature DB >> 22581011

Communicating the risks of medicines: time to move forward.

Gerald J Dal Pan.   

Abstract

Mesh：

Year:  2012        PMID： 22581011     DOI： 10.1097/MLR.0b013e31825852f0

Source DB:  PubMed          Journal:  Med Care        ISSN： 0025-7079            Impact factor:   2.983


× No keyword cloud information.
  8 in total

1.  How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?

Authors:  Jason C Hsu; Dennis Ross-Degnan; Anita K Wagner; Fang Zhang; Christine Y Lu
Journal:  Clin Ther       Date:  2015-05-11       Impact factor: 3.393

2.  Asthma Treatments and Mental Health Visits After a Food and Drug Administration Label Change for Leukotriene Inhibitors.

Authors:  Christine Y Lu; Fang Zhang; Matthew D Lakoma; Melissa G Butler; Vicki Fung; Emma K Larkin; Elyse O Kharbanda; William M Vollmer; Tracy Lieu; Stephen B Soumerai; Ann Chen Wu
Journal:  Clin Ther       Date:  2015-04-25       Impact factor: 3.393

3.  Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study.

Authors:  Aaron S Kesselheim; Sarah A McGraw; Sara Z Dejene; Paula Rausch; Gerald J Dal Pan; Brian M Lappin; Esther H Zhou; Jerry Avorn; Eric G Campbell
Journal:  Drug Saf       Date:  2017-06       Impact factor: 5.606

4.  Methodological approaches to evaluate the impact of FDA drug safety communications.

Authors:  Aaron S Kesselheim; Eric G Campbell; Sebastian Schneeweiss; Paula Rausch; Brian M Lappin; Esther H Zhou; John D Seeger; John S Brownstein; Steven Woloshin; Lisa M Schwartz; Timothy Toomey; Gerald J Dal Pan; Jerry Avorn
Journal:  Drug Saf       Date:  2015-06       Impact factor: 5.606

5.  Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem.

Authors:  Aaron S Kesselheim; Michael S Sinha; Eric G Campbell; Sebastian Schneeweiss; Paula Rausch; Brian M Lappin; Esther H Zhou; Jerry Avorn; Gerald J Dal Pan
Journal:  Drug Saf       Date:  2019-11       Impact factor: 5.606

6.  Near Real-time Surveillance for Consequences of Health Policies Using Sequential Analysis.

Authors:  Christine Y Lu; Robert B Penfold; Sengwee Toh; Jessica L Sturtevant; Jeanne M Madden; Gregory Simon; Brian K Ahmedani; Gregory Clarke; Karen J Coleman; Laurel A Copeland; Yihe G Daida; Robert L Davis; Enid M Hunkeler; Ashli Owen-Smith; Marsha A Raebel; Rebecca Rossom; Stephen B Soumerai; Martin Kulldorff
Journal:  Med Care       Date:  2018-05       Impact factor: 2.983

7.  Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis.

Authors:  Michael S Sinha; Clark C Freifeld; John S Brownstein; Macarius M Donneyong; Paula Rausch; Brian M Lappin; Esther H Zhou; Gerald J Dal Pan; Ajinkya M Pawar; Thomas J Hwang; Jerry Avorn; Aaron S Kesselheim
Journal:  JMIR Public Health Surveill       Date:  2018-01-05

8.  Consumer Understanding, Preferences, and Responses to Different Versions of Drug Safety Messages in the United States: A Randomized Controlled Trial.

Authors:  Lauren McCormack; R Craig Lefebvre; Carla Bann; Olivia Taylor; Paula Rausch
Journal:  Drug Saf       Date:  2016-02       Impact factor: 5.606
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.